Results from Monitoring Endosulfan and Dieldrin in Wide Hollow Creek, Yakima River Drainage, 2005-06
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Factors Influencing Pesticide Resistance in Psylla Pyricola Foerster and Susceptibility Inits Mirid
AN ABSTRACT OF THE THESIS OF: Hugo E. van de Baan for the degree ofDoctor of Philosopbv in Entomology presented on September 29, 181. Title: Factors Influencing Pesticide Resistance in Psylla pyricola Foerster and Susceptibility inits Mirid Predator, Deraeocoris brevis Knight. Redacted for Privacy Abstract approved: Factors influencing pesticide susceptibility and resistance were studied in Psylla pyricola Foerster, and its mirid predator, Deraeocoris brevis Knight in the Rogue River Valley, Oregon. Factors studied were at the biochemical, life history, and population ecology levels. Studies on detoxification enzymes showed that glutathione S-transferase and cytochrome P-450 monooxygenase activities were ca. 1.6-fold higherin susceptible R. brevis than in susceptible pear psylla, however, esterase activity was ca. 5-fold lower. Esterase activity was ca. 18-fold higher in resistant pear psylla than in susceptible D. brevis, however, glutathione S-transferase and cytochrome P-450 monooxygenase activities were similar. Esterases seem to be a major factor conferring insecticideresistance in P. Pvricola. Although the detoxification capacities of P. rivricola and D. brevis were quite similar, pear psylla has developed resistance to many insecticides in the Rogue River Valley, whereas D. brevis has remained susceptible. Biochemical factors may be important in determining the potential of resistance development, however, they are less important in determining the rate at which resistance develops. Computer simulation studies showed that life history and ecological factors are probably of greater importancein determining the rate at which resistance develops in P. pvricola and D. brevis. High fecundity and low immigration of susceptible individuals into selected populations appear to be major factors contributing to rapid resistance development in pear psylla compared with D. -
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
Prenatal Organochlorine Pesticide Exposure and the Disruption of Steroids and Reproductive Hormones in Cord Blood : Title the Hokkaido Study
Prenatal organochlorine pesticide exposure and the disruption of steroids and reproductive hormones in cord blood : Title The Hokkaido study Araki, Atsuko; Miyashita, Chihiro; Mitsui, Takahiko; Goudarzi, Houman; Mizutani, Futoshi; Chisaki, Youichi; Itoh, Author(s) Sachiko; Sasaki, Seiko; Cho, Kazutoshi; Moriya, Kimihiko; Shinohara, Nobuo; Nonomura, Katsuya; Kishi, Reiko Environment international, 110, 1-13 Citation https://doi.org/10.1016/j.envint.2017.10.006 Issue Date 2018-01 Doc URL http://hdl.handle.net/2115/76437 © 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license Rights http://creativecommons.org/licenses/by-nc-nd/4.0/ Rights(URL) http://creativecommons.org/licenses/by-nc-nd/4.0/ Type article (author version) File Information ENVINT_2017_824_(final).pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP 1 2 3 4 5 6 1 Prenatal organochlorine pesticide exposure and the disruption of steroids and 7 8 2 reproductive hormones in cord blood: The Hokkaido Study 9 10 3 Atsuko Arakia, Chihiro Miyashitaa, Takahiko Mitsuib,c, Houman Goudarzia,d, Futoshi 11 12 4 Mizutanie, Youichi Chisakie, Sachiko Itoha, Seiko Sasakif, Kazutoshi Chog, Kimihiko 13 14 5 Moriyah, Nobuo Shinoharah, Katsuya Nonomurah,i, and Reiko Kishia 15 16 6 17 18 7 aCenter for Environmental and Health Sciences, Hokkaido University, Kita 12, Nishi 7, 19 20 8 Sapporo, Hokkaido, Japan 21 22 b 23 9 Department of Urology, Hokkaido University Hospital, Kita 15, Nishi 7, Sapporo, 24 25 10 Hokkaido, Japan 26 -
Federal Register/Vol. 71, No. 80/Wednesday, April 26
Federal Register / Vol. 71, No. 80 / Wednesday, April 26, 2006 / Proposed Rules 24615 section for a location to examine the Definition August 2, 1996, that are associated with regulatory evaluation. (h) For the purposes of this AD, an HPT actions proposed herein were module exposure is when the 1st stage HPT previously counted as reassessed at the List of Subjects in 14 CFR Part 39 rotor and 2nd stage HPT rotor are removed time of the completed Reregistration from the HPT case, making the 2nd stage Eligibility Decision (RED), Report of the Air transportation, Aircraft, Aviation HPT vanes and 2nd stage HPT air seal safety, Safety. Food Quality Protection Act (FQPA) assembly accessible in the HPT case. Tolerance Reassessment Progress and The Proposed Amendment Alternative Methods of Compliance Risk Management Decision (TRED), or Federal Register action. Under the authority delegated to me (i) The Manager, Engine Certification by the Administrator, the Federal Office, has the authority to approve DATES: Comments must be received on alternative methods of compliance for this or before June 26, 2006. Aviation Administration proposes to AD if requested using the procedures found amend 14 CFR part 39 as follows: in 14 CFR 39.19. ADDRESSES: Submit your comments, identified by docket identification (ID) PART 39—AIRWORTHINESS Related Information number EPA–HQ–OPP–2005–0459, by DIRECTIVES (j) None. one of the following methods: • Issued in Burlington, Massachusetts, on Federal eRulemaking Portal: http:// 1. The authority citation for part 39 April 19, 2006. www.regulations.gov. Follow the on-line continues to read as follows: instructions for submitting comments. -
Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves. -
Endosulfan Sulfate Hazard Summary Identification
Common Name: ENDOSULFAN SULFATE CAS Number: 1031-07-8 RTK Substance number: 2988 DOT Number: UN 2761 Date: May 2002 ------------------------------------------------------------------------- ------------------------------------------------------------------------- HAZARD SUMMARY WORKPLACE EXPOSURE LIMITS The following information is based on Endosulfan: The following exposure limits are for Endosulfan: * Endosulfan Sulfate can affect you when breathed in and may be absorbed through the skin. NIOSH: The recommended airborne exposure limit is 3 * High exposure to Endosulfan Sulfate may cause 0.1 mg/m averaged over a 10-hour workshift. headache, giddiness, blurred vision, nausea, vomiting, diarrhea, and muscle weakness. Severe poisoning may ACGIH: The recommended airborne exposure limit is 3 cause convulsions and coma. 0.1 mg/m averaged over an 8-hour workshift. * Repeated and high exposures may affect the heart causing irregular heartbeats (arrhythmia). * The above exposure limits are for air levels only. When * CONSULT THE NEW JERSEY DEPARTMENT OF skin contact also occurs, you may be overexposed, even HEALTH AND SENIOR SERVICES HAZARDOUS though air levels are less than the limits listed above. SUBSTANCE FACT SHEET ON ENDOSULFAN. WAYS OF REDUCING EXPOSURE IDENTIFICATION * Where possible, enclose operations and use local exhaust Endosulfan Sulfate is a sand-like powder which is not ventilation at the site of chemical release. If local exhaust produced or used commercially. It occurs from the precursor ventilation or enclosure is not used, respirators should be Endosulfan, which is used as a pesticide. worn. * Wear protective work clothing. REASON FOR CITATION * Wash thoroughly immediately after exposure to * Endosulfan Sulfate is on the Hazardous Substance List Endosulfan Sulfate and at the end of the workshift. -
Food and Chemical Toxicology 64 (2014) 1–9
Food and Chemical Toxicology 64 (2014) 1–9 Contents lists available at ScienceDirect Food and Chemical Toxicology journal homepage: www.elsevier.com/locate/foodchemtox Taurine reverses endosulfan-induced oxidative stress and apoptosis in adult rat testis ⇑ Hamdy A.A. Aly a,b, , Rasha M. Khafagy c a Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia b Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt c Physics Department, Girls College for Arts, Science and Education, Ain Shams University, Cairo, Egypt article info abstract Article history: The present study was aimed to investigate the mechanistic aspect of endosulfan toxicity and its protec- Received 26 March 2013 tion by taurine in rat testes. Pre-treatment with taurine (100 mg/kg/day) significantly reversed the Accepted 11 November 2013 decrease in testes weight, and the reduction in sperm count, motility, viability and daily sperm produc- Available online 19 November 2013 tion in endosulfan (5 mg/kg/day)-treated rats. Sperm chromatin integrity and epididymal L-carnitine were markedly decreased by endosulfan treatment. Endosulfan significantly decreased the level of serum Keywords: testosterone and testicular 3b-HSD, 17b-HSD, G6PDH and LDH-X. Sperm Dwm and mitochondrial cyto- Endosulfan chrome c content were significantly decreased after endosulfan. Testicular caspases-3, -8 and -9 activities Taurine were significantly increased but taurine showed significant protection from endosulfan-induced apopto- Sperm Apoptosis sis. Oxidative stress was induced by endosulfan treatment as evidenced by increased H2O2 level and LPO Oxidative stress and decreased the antioxidant enzymes SOD, CAT and GPx activities and GSH content. -
QSAR Model for Androgen Receptor Antagonism
s & H oid orm er o t n S f a l o S l c a Journal of i n e Jensen et al., J Steroids Horm Sci 2012, S:2 r n u c o e DOI: 10.4172/2157-7536.S2-006 J ISSN: 2157-7536 Steroids & Hormonal Science Research Article Open Access QSAR Model for Androgen Receptor Antagonism - Data from CHO Cell Reporter Gene Assays Gunde Egeskov Jensen*, Nikolai Georgiev Nikolov, Karin Dreisig, Anne Marie Vinggaard and Jay Russel Niemelä National Food Institute, Technical University of Denmark, Department of Toxicology and Risk Assessment, Mørkhøj Bygade 19, 2860 Søborg, Denmark Abstract For the development of QSAR models for Androgen Receptor (AR) antagonism, a training set based on reporter gene data from Chinese hamster ovary (CHO) cells was constructed. The training set is composed of data from the literature as well as new data for 51 cardiovascular drugs screened for AR antagonism in our laboratory. The data set represents a wide range of chemical structures and various functions. Twelve percent of the screened drugs were AR antagonisms; three out of six statins showed AR antagonism, two showed cytotoxicity and one was negative. The newly identified AR antagonisms are: Lovastatin, Simvastatin, Mevastatin, Amiodaron, Docosahexaenoic acid and Dilazep. A total of 874 (231 positive, 643 negative) chemicals constitute the training set for the model. The Case Ultra expert system was used to construct the QSAR model. The model was cross-validated (leave-groups-out) with a concordance of 78.4%, a specificity of 86.1% and a sensitivity of 57.9%. -
1 of 3 GC+LC-USA
Updated: 07/18/2016 1 of 3 GC+LC-USA Limit of Quantitation (LOQ): 0.010 mg/kg (ppm) Sample Types: Low Fat Content Samples Minimum Sample Size: 100 grams (~1/4 pound). Certain products require more for better sample representation. Instrument: GC-MS/MS and LC-MS/MS Turnaround: 24-48 hours Accreditation: Part of AGQ USA's ISO/IEC 17025 Accreditation Scope 4,4'-Dichlorobenzophenone Bupirimate Cyantraniliprole Diflufenican Abamectin Buprofezin Cyazofamid Dimethoate Acephate Butachlor Cycloate Dimethoate (Sum) Acequinocyl Butocarboxim Cycloxydim Dimethomorph Acetamiprid Butralin Cyflufenamid Diniconazole Acetochlor Cadusafos Cyfluthrin Dinocap Acrinathrin Captafol Cymoxanil Dinotefuran Alachlor Captan Cyproconazole Diphenylamine Aldicarb Captan (Sum) Cyprodinil Disulfoton Aldicarb (Sum) Carbaryl Cyromazine Disulfoton (Sum) Aldicarb-sulfone Carbofuran DDD-o,p Disulfoton-sulfone Aldicarb-sulfoxide Carbofuran-3-hydroxy DDD-p,p +DDT-o,p Disulfoton-sulfoxide Aldrin Carbophenothion DDE-o,p Ditalimfos Ametryn Carbosulfan DDE-p,p Diuron Amitraz Carboxine DDT (Sum) Dodemorph Atrazine Carfentrazone-ethyl DDT-p,p Dodine Azadirachtin Chinomethionat DEET Emamectin Benzoate Azamethiphos Chlorantraniliprole Deltamethrin Endosulfan (A+B+Sulf) Azinphos-ethyl Chlordane Demeton Endosulfan Alfa Azinphos-methyl Chlordane Trans Demeton-S-methyl-sulfone Endosulfan Beta Azoxystrobin Chlorfenapyr Desmedipham Endosulfan Sulfate Benalaxyl Chlorfenson Diafenturion Endrin Ben-Carb-TPM (Sum) Chlorfenvinphos Dialifos EPN Bendiocarb Chlorfluazuron Diazinon Epoxiconazole -
Customs Tariff - Schedule
CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels. -
(12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al
USOO8486374B2 (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin et al. (45) Date of Patent: Jul. 16, 2013 (54) HYDROPHILIC, NON-AQUEOUS (56) References Cited PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES U.S. PATENT DOCUMENTS 1,159,250 A 11/1915 Moulton 1,666,684 A 4, 1928 Carstens (75) Inventors: Dov Tamarkin, Maccabim (IL); Meir 1924,972 A 8, 1933 Beckert Eini, Ness Ziona (IL); Doron Friedman, 2,085,733. A T. 1937 Bird Karmei Yosef (IL); Alex Besonov, 2,390,921 A 12, 1945 Clark Rehovot (IL); David Schuz. Moshav 2,524,590 A 10, 1950 Boe Gimzu (IL); Tal Berman, Rishon 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely LeZiyyon (IL); Jorge Danziger, Rishom 2,767,712 A 10, 1956 Waterman LeZion (IL); Rita Keynan, Rehovot (IL); 2.968,628 A 1/1961 Reed Ella Zlatkis, Rehovot (IL) 3,004,894 A 10/1961 Johnson et al. 3,062,715 A 11/1962 Reese et al. 3,067,784. A 12/1962 Gorman (73) Assignee: Foamix Ltd., Rehovot (IL) 3,092.255. A 6, 1963 Hohman 3,092,555 A 6, 1963 Horn 3,141,821 A 7, 1964 Compeau (*) Notice: Subject to any disclaimer, the term of this 3,142,420 A 7/1964 Gawthrop patent is extended or adjusted under 35 3,144,386 A 8/1964 Brightenback U.S.C. 154(b) by 1180 days. 3,149,543 A 9, 1964 Naab 3,154,075 A 10, 1964 Weckesser 3,178,352 A 4, 1965 Erickson (21) Appl. -
Toxicological Review of Chlordane (Technical)
TOXICOLOGICAL REVIEW of CHLORDANE (TECHNICAL) (CAS No. 12789-03-6) In Support of Summary Information on the Integrated Risk Information System (IRIS) December 1997 U.S. Environmental Protection Agency Washington, DC TABLE OF CONTENTS Authors and Reviewers ...................................................... iv Foreword ................................................................ vii 1.0 Introduction ...........................................................1 2.0 Toxicokinetics Relevant to Assessments .....................................2 3.0 Absorption, Metabolism, Distribution, Excretion, and Toxicokinetics .............3 4.0 Hazard Identification ....................................................5 4.1 Studies in Humans ....................................................5 4.1.1 Noncancer Effects in Humans .......................................5 4.1.2 Cancer Effects in Humans .........................................9 4.1.2.1 Case-control studies ........................................9 4.1.2.2 Occupational cohort studies .................................11 4.1.2.3 Case reports .............................................13 4.2 Subchronic and Chronic Studies and Cancer Bioassays in Animals—Oral and Inhalation ......................................................15 4.3 Reproductive/Developmental Studies—Oral and Inhalation .................... 26 4.4 Other Toxicologically Relevant Studies ...................................30 4.4.1 Mechanistic Studies .............................................30 4.4.2 Genotoxicity ..................................................30